Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are widely used to treat non-small cell lung cancer (NSCLC). However, acquired resistance is unavoidable, impairing the anti-tumor effects of EGFR-TKIs. It is reported that histone...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Peng-Fei, Gao, Wei-Wei, Sun, Cui-Lan, Ma, Tai, Hao, Ji-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289310/
https://www.ncbi.nlm.nih.gov/pubmed/32452893
http://dx.doi.org/10.1097/CM9.0000000000000823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289310/
https://www.ncbi.nlm.nih.gov/pubmed/32452893
http://dx.doi.org/10.1097/CM9.0000000000000823

Ejemplares similares